Remarkably, several chemotherapeutic agents used traditionally to kill tumor cells in cancer patients as well as kinase inhibitors that target STAT3 and tyrosine kinases, have recently been found to be efficacious in altering the myeloid-mediated immunosuppressive environment, leading to adaptive T cell immunity and tumor regression9, 14, 15, 16, 17, 18, 19. The gene discussed is STAT3; the disease is cancer.